Home › Non-Small Cell Lung Cancer › Illinois › Arlington Heights
Non-Small Cell Lung Cancer clinical trials in Arlington Heights, IL
12 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around Arlington Heights (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RecruitingPhase 3
- Advocate Good Shepherd Hospital, Barrington · 9 mi away
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RecruitingPhase 3
- Illinois Cancer Specialists, Arlington Heights
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
RecruitingPhase 3
- Illinois Cancer Specialists, Arlington Heights
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
RecruitingObservational study
- Northwest Oncology & Hematology, Elk Grove Village · 6 mi away
An External Control Arm Study in Non-Small Cell Lung Cancer
RecruitingObservational study
- Northwest Oncology and Hematology, Rolling Meadows · 2 mi away
- Northwest Oncology and Hematology, Elk Grove · 6 mi away
- Northwest Oncology and Hematology, Hoffman Estates · 6 mi away
- and 1 more
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RecruitingPhase 2/3
- Local Institution - 007-883-A, Arlington Heights
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RecruitingPhase 3
- Illinois Cancer Specialists, Arlington Heights
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
RecruitingPhase 3
- Northwest Oncology & Hematology, Barrington · 9 mi away
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RecruitingPhase 2
- Advocate Good Shepherd Hospital, Barrington · 9 mi away
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2
- Advocate Good Shepherd Hospital, Barrington · 9 mi away
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2/3
- Advocate Good Shepherd Hospital, Barrington · 9 mi away
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RecruitingObservational study
- Advocate Good Shepherd Hospital, Barrington · 9 mi away
Non-Small Cell Lung Cancer trials in other cities
- Houston, TX145 studies
- New York City, NY121 studies
- Arlington, VA104 studies
- Nashville, TN97 studies
- Boston, MA90 studies
- Los Angeles, CA87 studies
- St. Louis, MO73 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH57 studies
- Washington, DC55 studies
Other studies in Arlington Heights
- Colorectal Cancer12 studies
- Lung Cancer9 studies
- Breast Cancer7 studies
- Heart Failure7 studies
- Metastatic Cancer6 studies
- Ulcerative Colitis6 studies
- Colon Cancer6 studies
- Ovarian Cancer5 studies
- Obesity5 studies
- Overweight5 studies
- Prostate Cancer3 studies
- Skin Conditions3 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.